Cell therapy has the potential to cure disease through replacement of malfunctioning cells. Although the tissue stem cell (TSC) is thought to be the optimal therapeutic cell, transplantation of TSC/progenitor cell mixtures has saved lives. We previously purified the mouse tracheobronchial epithelial TSCs and reported that in vitro amplification generated numerous TSCs. However, these cultures also contained TSC-derived progenitor cells and TSC repurification by flow cytometry compromised TSC self-renewal. These limitations prompted us to determine if a TSC/progenitor cell mixture would repopulate the injured airway epithelium. We developed a cell transplantation protocol and demonstrate that transplanted mouse and human tracheobronchial epithelial TSC/progenitor cell mixtures are 20-25% of airway epithelial cells, actively contribute to epithelial repair, and persist for at least 43 days. At 2 weeks after transplantation, TSCs/progenitor cells differentiated into the three major epithelial cell types: basal, secretory, and ciliated. We conclude that cell therapy that uses adult tracheobronchial TSCs/progenitor cells is an effective therapeutic option.
The data presented in this study support the conclusion that cell therapy that uses adult tracheobronchial tissue stem/progenitor cells is an effective therapeutic option.
Cell therapy for chronic disease will likely require transplantation of a cell that has extensive mitotic and differentiation potential. A tissue stem cell (TSC) is a progenitor subtype that self-renews (replaces itself) and generates each of the cell types found in the home tissue of the TSC (acts as a multipotential progenitor) (1) . Thus, cell therapy initiatives often focus on TSCs.
Functional analyses from our group and others demonstrated that the adult mouse tracheobronchial epithelium is maintained and repaired by a TSC (2) (3) (4) (5) (6) (7) (8) (9) . We reported that the mouse tracheobronchial epithelial TSC is a CD49f
Bright /Sca1 1 /Aldefluor Bright basal cell subtype (3) . These TSCs are extremely rare: there are approximately 100 TSCs per airway, and TSCs are only 0.05% of all epithelial cells.
We also reported that the mouse tracheobronchial TSCs generated a unique clone type, the rim clone, when cultured in vitro (2, 3) . TSC culture as rim clones permitted TSC amplification and maintained TSC self-renewal and multipotential differentiation potential, the functional properties required of a therapeutic cell. However, TSC-derived rim clones also contained non-TSC basal progenitor cells, and repurification of amplified TSCs from rim clones by flow sorting compromised TSC self-renewal, as assayed by clone formation. These limitations caused us to question whether cell therapy using a TSC/progenitor inoculum was feasible.
The purpose of this study was to test the hypothesis that a mixture of adult TSCs/progenitor cells would repopulate the airway epithelium after injury. We report successful development of a transplantation assay that uses a well characterized epithelial injury/repair model. Using this model, we demonstrate that mouse TSCs/progenitor cells reconstitute the conducting airway epithelium of mice after transplantation and exhibit multilineage differentiation. We extend these results to humans by demonstrating that unfractionated human basal progenitor cells can also be used as an effective form of cell therapy.
Materials and Methods
Complete methods are provided in the online supplement.
Animals
All procedures involving animal use were approved by the National Jewish Health (Denver, CO) Institutional Animal Care and Use Committee. Mice were maintained in an Association for Assessment and Accreditation of Laboratory Animal Care-approved facility and screened for pathogens on a quarterly basis. The strains varied by experiment, and are detailed subsequently here.
Naphthalene Treatment
Naphthalene (NA) was prepared and administered as previously reported (10) . NA dose was selected to cause greater than 95% depletion of the Clara cell secretory protein (CCSP) 1 cell population by Recovery Day 3.
TSC Quantification
Female FVB/n mice, 6-8 weeks old, were treated with NA. On Recovery Days 6, 40, and 80, tracheal epithelial cells were recovered by dispase/collagenase/trypsin digestion and clone-forming cell frequency was determined by limiting dilution (3).
Mouse TSC Purification and Expansion
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Bright tracheal TSCs were purified from Rosa-LacZ mice by flow sorting (3). TSC were expanded on irradiated NIH3T3 feeder layers (3) . Stem/progenitor cells were recovered by double trypsinization and resuspended in 13 PBS.
Tracheal Xenografts
Test cells, 1 3 10 6 irradiated fibroblast feeder cells, or mouse stem/progenitor cells were introduced into the lumen of freeze-thawed Swiss-Webster rat tracheas. This xenograft was positioned in a subcutaneous pocket in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. The xenograft and host trachea were recovered at various time points.
Human Cells
Human tracheobronchial tissue was procured from National Disease Research Interchange under National Jewish Institutional Review Boardapproved protocols. Epithelial cells were purified and cultured in bronchial epithelial growth medium (11, 12) . Passage 3 cells were transduced with MISSION pLKO.1-puro TurboGFP lentiviral particles following the manufacturer's instructions (Sigma, St. Louis, MO). At 72 hours after transduction, cells were collected and resuspended in sterile 13 PBS. Approximately 80% of cells were green fluorescent protein (GFP) 1 
.
Transplantation Protocol
The protocol was developed using passage 1 stem/progenitor cells (test cells) that were recovered from ROSA26-LacZ transgenic mice. Pilot studies used NOD/SCID and C57Bl/6 mice that were treated with corn oil or NA. On Recovery Day 2 or 4, mice were anesthetized and the vocal cords visualized. Aliquots of 5 3 10 4 , 2.5 3 10 5 , or 10 6 cells in 30 ml 13 PBS were instilled into the trachea (13) . For intravenous cell delivery studies, cells were injected into the tail vein with a 26-gauge needle. Subsequent studies used the optimal transplantation protocol, NOD/SCID host mice, and an inoculum of 2.5 3 10 5 test cells.
Histology
Xenografts, tracheal tissue, and lung tissue were fixed, paraffin embedded, and immunostained using published methods (10, (14) (15) (16) (17) (18) . Mouse test cells were detected by 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside staining (14, 15) . Human test cells were identified via immunodetection of the GFP tag. Differentiated cell type frequency and contribution to the epithelial cell pool were quantified as previously described (15, 16) .
Statistical Analyses
All statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). For normally distributed data sets, differences were evaluated using Student's t test. For nonnormally distributed data sets, differences were evaluated by the Mann-Whitney test. P values less than 0.05 were considered significant. All analyses included trachea or lung tissue samples recovered from three to four mice.
Results
Mouse TSCs/Progenitor Cells Undergo Limited Differentiation Ex Vivo
The lung has a remarkable host defense system that imposes multiple barriers to successful cell transplantation. Thus, we first evaluated mouse TSC/progenitor cell differentiation using the rat tracheal xenograft system (19, 20 (22) . Because NA injury is frequently used to activate mouse airway epithelial TSCs in vivo (2, 14, 15) , and this model was also used in combination with total body irradiation for ESC transplantation, we determined if NA treatment depleted the TSC population.
Groups of adult female FVB/n mice were treated with vehicle or 300 mg/kg NA and recovered for 6, 40, or 80 days. Tracheal cells were recovered by dispase/collagenase/trypsin digestion, and TSC frequency was determined by the limiting dilution method (3) . This study demonstrated that NA treatment significantly decreased TSC frequency on Recovery Days 6 and 40 ( Figure 2 ). In contrast, TSC frequency was normal on Recovery Day 80. These data suggested that NA injury could be used to condition the host before transplantation of TSCs/progenitor cells.
Transplantation Protocol Development
Our first goal was to determine if repopulation of the conducting airway epithelium was facilitated by NA injury. Pilot studies (summarized in Figure 3 ) demonstrated that LacZ-labeled TSCs/progenitor (test) cells failed to repopulate the airways of vehicletreated mice (uninjured). In contrast, the trachea and intrapulmonary airways of NA-injured mice were repopulated by test cells. Test cells did not repopulate the parenchyma, a lung region that is not injured by NA exposure.
Second, we determined the optimal route, dose, and timing for test cell transplantation. We show that transplantation on Recovery Day 2 was successful. In contrast, neither the airways nor the parenchyma were repopulated by test cells that were transplanted on Recovery Day 4. Intratracheal instillation permitted airway-specific repopulation, whereas intravenous infusion was unsuccessful. A dose-response study used intratracheal instillation on Recovery Day 2, and showed that as few as 50,000 TSCs/progenitor cells repopulated the airway epithelium, and as many as one million cells were well tolerated.
Third, we determined if test cells repopulated the airway epithelium of syngeneic C57Bl/6 mice or immunecompromised NOD/SCID/T-cell receptor (TCR)-g knockout (NOD/SCID) hosts. These studies demonstrated successful and specific repopulation of the tracheal and intrapulmonary airway epithelium by test cells in both host types. Finally, we used the optimal transplantation parameters (Figure 3) , NOD/SCID host mice, and an inoculum of 2.5 3 10 5 test cells were used to evaluate test cell persistence. Testderived cells were detected 7, 14, 35, and 43 days after transplantation ( Figure 3 ).
Transplanted Mouse TSCs/Progenitor Cells Repopulate the Conducting Airway Epithelium
We used the optimal transplantation protocol (Figure 3 ), NOD/SCID host mice, and an inoculum of 2.5 3 10 5 test cells to evaluate test cell location, abundance, and differentiation. Whole-mount analysis of the tracheobronchial airways identified clusters of test-derived cells in the trachea and main stem bronchi ( Figures 4A-4C ). These clusters were common throughout the trachea and its subregions ( Figure 4E ). However, cluster size varied within a single host animal and across hosts ( Figure 4F ). The bronchial airways were also repopulated with clusters of test-derived cells ( Figures 4D and 4E) . As for the trachea, the frequency of test-derived cells in the bronchial epithelium varied within and among hosts ( Figure 4G ). Few test-derived cells were identified in the terminal bronchioles, and none were located in the parenchyma.
Transplanted TSCs/Progenitor Cells Exhibit Multilineage Differentiation
Test-derived cell differentiation was evaluated by codetection of the LacZ tag and differentiation markers in the trachea ( Figures 5A-5C ) and intrapulmonary airways (Figures 5E-5H) 2 weeks after transplantation. Quantification demonstrated that test-derived cells generated basal and secretory cells at a frequency that was equivalent to that of host-derived (LacZ 2 ) tracheal cells ( Figure 5D ). In contrast, differentiation of test-derived cells to the ciliated cell phenotype was significantly less than that observed for host-derived cells. In the intrapulmonary airways, testderived cell differentiation to basal and ciliated cells was similar to the host ( Figure 5I ). However, test-derived cells generated significantly fewer secretory cells than did host-derived cells.
Transplanted Human TSCs/Progenitor Cells Repopulate the Tracheobronchial and Intrapulmonary Airways
One-million GFP-labeled human TSCs/progenitor (test) cells were transplanted using the optimal transplantation protocol. Histological studies identified GFP 1 test-derived cells in the trachea (Figures 6A-6C ) and intrapulmonary airways (Figures 6G-6I ) 2 weeks after transplantation. Testderived cells were not detected in the parenchymal epithelium.
In the trachea, test-derived cells were typically less abundant than host-derived cells ( Figure 6D ). In mice that were well repopulated, hostand test-derived cells were equally represented throughout the proximalto-distal axis of the trachea ( Figure 6E ). The majority of test-derived cells did not express the basal cell markers, K5 ( Figure 6F ) or K14 (data not shown). Differentiation of test-derived cells to a mucus cell phenotype was significantly greater than the host cells ( Figure 6F ), whereas differentiation of test-derived cells to the ciliated cell phenotype was significantly less than the host cells ( Figure 6F ). In agreement with these data, the contribution of test-derived cells to the basal and ciliated cell pools was less than host-derived cells, whereas their contribution to the mucus cell pool was greater than host-derived cells (data not shown).
Human test-derived cells were also identified in the intrapulmonary airways ( Figures 6A-6C ). Test-derived cells were most frequent along the main axial pathway, where they comprised approximately one-half of the epithelium ( Figure 6J ). However, test-derived cells were less frequent than host-derived cells in the bronchial and terminal bronchiolar epithelium ( Figure 6K ). In the main axial airway, a minority of test-derived cells express K5 ( Figure 6L ), whereas the majority expressed secretory (Mucin 5B) and ciliated cell markers ( Figure 6L ). Testderived cells were a rare contributor to the basal cell pool in bronchial airways, but comprised approximately one-half of the secretory and ciliated cell pools ( Figures 6F, 6H, and 6J ). 
Discussion
Cell therapy has the potential to cure lung disease through replacement of malfunctioning cells. Although the TSC is thought to be the optimal therapeutic cell, evidence from nonpulmonary tissues demonstrated that transplantation of TSC/progenitor cell mixtures was an effective treatment approach (e.g., see Reference 23). We now show that transplanted mouse and human tracheobronchial TSC/progenitor cell mixtures reconstitute the injured airway epithelium within 2 weeks. We conclude that adult tracheobronchial TSCs/progenitors can be used as cell therapy.
Because chronic lung disease frequently involves the conducting airway epithelium, cell therapy has frequently focused on this tissue (Tables 1 and 2 ). Previous studies used a variety of methods (host conditioning, delivery route, and treatment time [22, [24] [25] [26] ). The present study narrows these options and provides a transplantation model that can be used to test additional stem and progenitor cell preparations.
We and others have reported that NA-induced injury is dependent on dose and genetic background (27) (28) (29) (30) . For example, high-dose NA treatment results in 95% depletion of the CCSP 1 cell population on Recovery Day 3. This injury level can be achieved by varying the NA dose according to genetic background (e.g., FVB/n mice, 300 mg/kg [10] ; C57Bl/6 mice, 250 mg/kg [30] ). In the present study, NOD/SCID host mice were treated with 275 mg/kg NA. This dose caused extensive depletion of the airway epithelial progenitor cell pool, and was associated with effective repopulation by transplanted TSCs/progenitor cells. In contrast with our study, Rosen and colleagues (22) reported that NA injury did not permit effective cell therapy by ESC. Based on our knowledge of NA injury, we speculate that ineffective transplantation in C57Bl/6 mice conditioned with 200 mg/kg NA was due to suboptimal airway epithelial injury.
Previous studies also demonstrated that NA toxicity is limited to the conducting airway epithelium, and that it did not injure the parenchyma. In the present study, transplanted TSCs/progenitor cells repopulated the airway epithelium, but not parenchymal tissues. These data suggest that the lack of parenchymal injury in NA-treated mice prevents aberrant seeding of the alveolar epithelium. Furthermore, they also suggest that cell therapy for chronic airway disease should use a host-conditioning regimen that causes extensive and specific injury to the conducting airway epithelium.
Previous studies and preliminary analysis (data not shown) indicate that NA injury has no detectable effect on vasculature integrity, whereas many agents that are used to study epithelial injury and repair (bleomycin, influenza, and radiation) target multiple lung tissues, including the vasculature. In the present study, we report that intravenous delivery of TSCs/progenitor cells to NA-treated mice did not result in effective repopulation by transplanted TSCs/progenitor cells. These data are in contrast to the report that intravenous delivery was an effective route in mice that were conditioned with a combination of low-dose NA and total body irradiation (22) . Knowing that radiation compromises vascular integrity, we suggest that the Rosen group's successful use of infused cells was due radiation-induced loss of vascular integrity. Collectively, these data suggest that the host-conditioning method determines the effective cell delivery route.
High-dose NA-induced airway epithelial injury is repaired in two stages. First, the uninjured epithelial cells spread and re-establish the epithelial barrier (29, 31) . Second, tracheobronchial and bronchiolar TSCs proliferate and generate differentiated progeny that repopulate the epithelium (14) (15) (16) . Ciliated cells are among the first differentiated cells that are replaced by the tracheobronchial TSCs, and are first detected on Recovery Day 3 (10) .
We report that transplantation on Recovery Day 2 resulted in effective repopulation, whereas transplantation on Recovery Day 4 was unsuccessful. Knowing that ciliated cells sweep the extracellular lining fluid and associated particles from the airway lumen, we speculate that the effective timeframe for cell transplantation is limited by ciliated cell-mediated clearance of transplanted cells. These data suggest that effective host conditioning in diseases that exhibit ciliated cell hypoplasia will require little host conditioning, whereas a hostconditioning regimen that compromises ciliated cell function will be needed in patients with normal ciliated cell frequency and function.
Successful TSC transplantation is thought to be dependent on hostconditioning regimes that decrease TSC frequency in the niche. In the present study, we show that high-dose NA exposure decreases the TSC population by approximately 75% on Recovery Day 6 ( Figure 2 ). This depletion indicates that NA treatment meets one criterion for effective host conditioning.
TSC depletion is also thought to increase TSC homing to the niche after transplantation. Previously identified respiratory epithelial TSC niches include the submucosal gland duct junction, the bronchiolar neuroepithelial body, and the bronchoalveolar duct junction (32) (33) (34) (35) (36) . In the present study, we report that test-derived mouse and human cells are found throughout the conducting airway epithelium. These data suggest that transplanted TSCs/progenitor cells did not preferentially repopulate the known niches. In light of our previous report that TSCs were located throughout the cartilaginous tracheal epithelium (2), we suggest two explanations for the relatively uniform distribution of test-derived cells in the tracheobronchial region. First, the tracheobronchial epithelium may contain multiple niches that are differentially sensitive to epithelial injury. The submucosal gland duct niche was defined by injuries that eliminated TSCs and progenitors in the surface airway epithelium (e.g., 350 mg/kg NA in FVB/n mice [33] , acid or detergent [32] ). In contrast, the injury achieved in our transplantation studies may have spared the submucosal gland duct niche, and TSC retention may have prevented repopulation by test-derived cells. Second, the TSC may generate its own niche (3, 9) . We previously reported that TSCs generated rim clones, and that the rim domain of the rim clone sequestered label-retaining cells (3) . Subsequent purification of these labelretaining cells demonstrated that they exhibited the TSC-specific phenotype, and that they generated rim clones with label-retaining TSCs in vitro (2) . These data suggest that the observed distribution of test-derived cells may stem from the TSC's intrinsic ability to create the niche de novo.
As previously shown for nonpulmonary tissues, the present study substantiates the notion that TSC/progenitor cell mixtures can be used as cell therapy for lung disease. Knowing that airway epithelial cells are long lived, additional studies are needed to determine if transplanted cells exhibit the same longevity. Similarly, the benefits of cell therapy require maintenance of the TSCs after transplantation. Additional single-cell lineage tracing and self-renewal studies are needed to address this aspect of cell therapy that uses a TSC/progenitor cell mixture.
Although the current transplantation model is appropriate to studies that evaluate the fundamental aspects of cell therapy, at least two limitations to the use of NA are recognized. First, NA-induced injury was used to condition the host. Although this treatment effectively prepared the mouse lung for cell therapy, the CyP-450 enzyme profile of the human airway epithelium (37) makes it unlikely that NA exposure will effectively condition the human lung. However, extensive knowledge of NA-induced injury in mice allows us to establish the characteristics of an effective hostconditioning strategy for airway-targeted cell therapy. We posit that extensive 
